STING1 and hepatocellular carcinoma: Given the potential risk of high doses of the STING agonist inducing T cell apoptosis and adverse effects (54), we selected the 2 mg/kg weekly dose that showed anti-HCC activity without limiting toxicity in mice with liver damage for further testing of the efficacy and safety of the treatment.